image
Healthcare - Biotechnology - NASDAQ - US
$ 7.18
-0.692 %
$ 153 M
Market Cap
-1.58
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Jun, 21, 2025.

The intrinsic value of one ENTA stock under the worst case scenario is HIDDEN Compared to the current market price of 7.18 USD, Enanta Pharmaceuticals, Inc. is HIDDEN

This DCF valuation model was last updated on Jun, 21, 2025.

The intrinsic value of one ENTA stock under the base case scenario is HIDDEN Compared to the current market price of 7.18 USD, Enanta Pharmaceuticals, Inc. is HIDDEN

This DCF valuation model was last updated on Jun, 21, 2025.

The intrinsic value of one ENTA stock under the best case scenario is HIDDEN Compared to the current market price of 7.18 USD, Enanta Pharmaceuticals, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart ENTA

image
$8.5$8.5$8.0$8.0$7.5$7.5$7.0$7.0$6.5$6.5$6.0$6.0$5.5$5.5$5.0$5.0$4.5$4.5$4.0$4.0Jan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 AprMay '25May '2515 May15 MayJun '25Jun '2515 Jun15 Jun
FINANCIALS
67.6 M REVENUE
-14.61%
-122 M OPERATING INCOME
11.31%
-116 M NET INCOME
13.28%
-78.8 M OPERATING CASH FLOW
23.64%
58.2 M INVESTING CASH FLOW
208.69%
-27.6 M FINANCING CASH FLOW
-13.94%
14.9 M REVENUE
-11.99%
-24.5 M OPERATING INCOME
-4.18%
-22.6 M NET INCOME
-1.59%
-13.5 M OPERATING CASH FLOW
19.72%
-4.37 M INVESTING CASH FLOW
-6.34%
-6.89 M FINANCING CASH FLOW
-38.13%
Balance Sheet Enanta Pharmaceuticals, Inc.
image
Current Assets 300 M
Cash & Short-Term Investments 248 M
Receivables 6.65 M
Other Current Assets 45 M
Non-Current Assets 76.8 M
Long-Term Investments 0
PP&E 73.3 M
Other Non-Current Assets 3.45 M
65.89 %11.95 %19.47 %Total Assets$376.7m
Current Liabilities 57.5 M
Accounts Payable 8 M
Short-Term Debt 1.52 M
Other Current Liabilities 48 M
Non-Current Liabilities 190 M
Long-Term Debt 53.9 M
Other Non-Current Liabilities 136 M
3.23 %19.37 %21.77 %55.02 %Total Liabilities$247.8m
EFFICIENCY
Earnings Waterfall Enanta Pharmaceuticals, Inc.
image
Revenue 67.6 M
Cost Of Revenue 0
Gross Profit 67.6 M
Operating Expenses 189 M
Operating Income -122 M
Other Expenses -5.65 M
Net Income -116 M
80m80m60m60m40m40m20m20m00(20m)(20m)(40m)(40m)(60m)(60m)(80m)(80m)(100m)(100m)(120m)(120m)(140m)(140m)68m068m(189m)(122m)6m(116m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
100.00% GROSS MARGIN
100.00%
-179.92% OPERATING MARGIN
-179.92%
-171.58% NET MARGIN
-171.58%
-90.09% ROE
-90.09%
-30.81% ROA
-30.81%
-37.39% ROIC
-37.39%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Enanta Pharmaceuticals, Inc.
image
80m80m60m60m40m40m20m20m00(20m)(20m)(40m)(40m)(60m)(60m)(80m)(80m)(100m)(100m)(120m)(120m)20162016201720172018201820192019202020202021202120222022202320232024202420252025
Net Income -116 M
Depreciation & Amortization 2.34 M
Capital Expenditures -17.9 M
Stock-Based Compensation 26.8 M
Change in Working Capital 7.13 M
Others 7.59 M
Free Cash Flow -96.7 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Enanta Pharmaceuticals, Inc.
image
Wall Street analysts predict an average 1-year price target for ENTA of $49 , with forecasts ranging from a low of $24 to a high of $87 .
ENTA Lowest Price Target Wall Street Target
24 USD 234.26%
ENTA Average Price Target Wall Street Target
49 USD 582.45%
ENTA Highest Price Target Wall Street Target
87 USD 1111.70%
Price
Max Price Target
Min Price Target
Average Price Target
90908080707060605050404030302020101000Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26Jun '26Jun '26Jul '26Jul '26
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 16
6. Ownership
Insider Ownership Enanta Pharmaceuticals, Inc.
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
127 K USD 6
9-12 MONTHS
191 K USD 1
Bought
0 USD 0
0-3 MONTHS
256 K USD 1
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Enanta Pharmaceuticals' Partner AbbVie Receives U.S. FDA Approval of an Expanded Indication for MAVYRET® (glecaprevir/pibrentasvir) as the First and Only Treatment for People with Acute Hepatitis C Virus WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases, today announced that the U.S. Food and Drug Administration (FDA) has approved a label expansion for MAVYRET® (glecaprevir/pibrentasvir), an oral pangenotypic direct acting antiviral (DAA) therapy. It is now approved as the only eight-week treatment for adults and pediatric patients three. businesswire.com - 3 weeks ago
Enanta Pharmaceuticals to Present at the Jefferies Global Healthcare Conference WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases, today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference on Thursday, June 5, 2025 at 8:10 a.m. ET in New York, NY. A live webcast of the event will be accessible by visiting the “Even. businesswire.com - 1 month ago
Enanta Pharmaceuticals Announces Data from its Phase 2 Study of Zelicapavir in Children with Respiratory Syncytial Virus to be Presented at the 43rd Annual ESPID Meeting WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases, today announced that data from the Company's Phase 2 study of zelicapavir in young children infected with respiratory syncytial virus (RSV) will be available as an E-Poster at the 43rd Annual Meeting of the European Society for Paediatric Infectious Diseases (ESPID) 2025, being held May 2. businesswire.com - 1 month ago
Does Enanta Pharmaceuticals (ENTA) Have the Potential to Rally 189.58% as Wall Street Analysts Expect? The consensus price target hints at an 189.6% upside potential for Enanta Pharmaceuticals (ENTA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term. zacks.com - 1 month ago
Enanta Pharmaceuticals (ENTA) Reports Q2 Loss, Misses Revenue Estimates Enanta Pharmaceuticals (ENTA) came out with a quarterly loss of $1.06 per share versus the Zacks Consensus Estimate of a loss of $1.04. This compares to loss of $1.47 per share a year ago. zacks.com - 1 month ago
Enanta Pharmaceuticals Announces Respiratory Syncytial Virus Data Presentation at ESCMID Global 2025 WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals Announces Respiratory Syncytial Virus Data Presentation at ESCMID Global 2025. businesswire.com - 2 months ago
Enanta Pharmaceuticals (ENTA) Moves to Buy: Rationale Behind the Upgrade Enanta Pharmaceuticals (ENTA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. zacks.com - 4 months ago
Enanta Pharmaceuticals (ENTA) Reports Q1 Loss, Tops Revenue Estimates Enanta Pharmaceuticals (ENTA) came out with a quarterly loss of $1.05 per share versus the Zacks Consensus Estimate of a loss of $1.16. This compares to loss of $1.58 per share a year ago. zacks.com - 4 months ago
Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 2024 WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today reported financial results for its fiscal first quarter ended December 31, 2024. “2025 is primed to be a pivotal year for Enanta as we execute on multiple catalysts across our pipeline, including progression of our RSV compounds and expansion of our immunology portfolio. Recruitment for RSV. businesswire.com - 4 months ago
Enanta Pharmaceuticals to Appeal Ruling Related to ‘953 Patent Infringement Lawsuit WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today announced that the United States District Court of Massachusetts (“the Court”) has issued a ruling on a summary judgment motion filed by Pfizer, Inc. in connection with Enanta's patent infringement lawsuit seeking damages for infringement of U.S. Patent No. 11,358,953 (“the '953 Patent”) i. businesswire.com - 6 months ago
Enanta Pharmaceuticals (ENTA) Moves 7.2% Higher: Will This Strength Last? Enanta Pharmaceuticals (ENTA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term. zacks.com - 6 months ago
Enanta Pharmaceuticals Announces Positive Topline Results from First-in-Pediatrics Phase 2 Study Evaluating Zelicapavir for the Treatment of Respiratory Syncytial Virus (RSV) WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today announced positive topline results from the first-in-pediatrics Phase 2 study evaluating zelicapavir in hospitalized and non-hospitalized children aged 28 days to 36 months with respiratory syncytial virus (RSV). An antiviral effect was observed for the primary and secondary virology endpoi. businesswire.com - 6 months ago
8. Profile Summary

Enanta Pharmaceuticals, Inc. ENTA

image
COUNTRY US
INDUSTRY Biotechnology
MARKET CAP $ 153 M
Dividend Yield 0.00%
Description Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus. Enanta Pharmaceuticals, Inc. was founded in 1995 and is headquartered in Watertown, Massachusetts.
Contact 500 Arsenal Street, Watertown, MA, 02472 https://www.enanta.com
IPO Date March 21, 2013
Employees 131
Officers Mr. Paul J. Mellett Jr. Chief Financial & Administrative Officer Dr. Yat Sun Or Ph.D. Chief Scientific Officer Mr. Brendan Luu Chief Business Officer Ms. Jennifer Viera Executive Director of Investor Relations & Corporate Communications Mr. Nathaniel S. Gardiner J.D. Consultant Mr. Matthew P. Kowalsky J.D. Chief Legal Officer & Corporate Secretary Dr. Scott T. Rottinghaus M.D. Chief Medical Office Ms. Tara Lynn Kieffer Ph.D. Chief Product Strategy Officer Dr. Jay R. Luly Ph.D. President, Chief Executive Officer & Director